Clinical Trial Detail

NCT ID NCT02903160
Title Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.